Vidofludimus

Small moleculeexperimental

Clinical trial activity

10 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
9
Phase 3
3
Phase 4
0

Earliest trial started Mar 1, 2009 (NCT00820365)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1
Mol. weight
355.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sc12267
  • sc12267
  • sc12267

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05201638Phase 3Jan 12, 2022Immunic AG
NCT05134441Phase 3Nov 30, 2021Case Western Reserve University, Immunic AG
NCT05054140Phase 2Sep 30, 2021Case Western Reserve University, Immunic AG
NCT04516915Phase 2Jun 15, 2020Immunic AG, MODEPHARMA Limited, University of Warwick
NCT04379271Phase 2/Phase 3 (Phase 3)May 31, 2020FGK Clinical Research GmbH, Immunic AG
NCT03722576Phase 2Jun 30, 2019Arizona State University, Mayo Clinic
NCT03846219Phase 2Jan 28, 2019Immunic AG
NCT03341962Phase 2Mar 15, 2018Immunic AG
NCT01010581Phase 2Nov 1, 20094SC AG, Medical University of Bialystok
NCT00820365Phase 2Mar 1, 20094SC AG, University of Tuebingen
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Immunic AGFor profit7622018
4SC AGFor profit2212009
Case Western Reserve UniversityAcademic/Hospital2022021
Arizona State UniversityAcademic/Hospital1012019
FGK Clinical Research GmbHFor profit1012020
Mayo ClinicAcademic/Hospital1112019
Medical University of BialystokAcademic/Hospital1012009
MODEPHARMA LimitedFor profit1012020
University of TuebingenAcademic/Hospital1012009
University of WarwickAcademic/Hospital1112020
10 organizations
Page 1 / 1